Stocks Health care NVAX
NASDAQ · Health careNovavax Inc (NVAX)
Novavax Inc brought in $413.8M of revenue over the twelve months to June 30, 2026, down 61.6% from a year earlier. It posted a net loss of $247.7M. In fiscal 2025 capital spending exceeded operating cash flow by $250.2M. At June 30, 2026 it held $191.5M in cash against $291.5M of debt. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 6, 2026.
What Novavax Inc does
Novavax Inc is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NASDAQ under the ticker NVAX.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $1.1B | $440.3M | $2.58 | -$250.2M |
| 2024 | $682.2M | -$187.5M | -$1.23 | -$100.3M |
| 2023 | $983.7M | -$545.1M | -$5.41 | -$767.7M |
| 2022 | $2B | -$657.9M | -$8.42 | -$505M |
| 2021 | $1.1B | -$1.7B | -$23.44 | $265.5M |
| 2020 | $475.6M | -$418.3M | -$7.27 | -$97.2M |
Latest SEC filings
What Novavax Inc has filed recently, newest first. Each links to the original document on SEC EDGAR.
- August 7, 2026Passive stake (5% or more) SCHEDULE 13G
- August 6, 2026
- August 6, 2026
- August 6, 2026Quarterly report 10-Q · period to June 30, 2026
- June 23, 2026
- May 15, 2026Activist stake changed SCHEDULE 13D/A
- May 6, 2026
- May 6, 2026Quarterly report 10-Q · period to March 31, 2026
- April 30, 2026Passive stake (5% or more) SCHEDULE 13G
- April 27, 2026Passive stake changed SCHEDULE 13G/A
Questions about NVAX
What does Novavax Inc do?
Novavax Inc is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NASDAQ under the ticker NVAX.
Is Novavax Inc profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $247.7M on revenue of $413.8M.
How much revenue does Novavax Inc make?
Over the twelve months to June 30, 2026 Novavax Inc reported revenue of $413.8M. That is 61.6% less than a year earlier.
When did Novavax Inc last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 6, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the passive stake (5% or more) from August 7, 2026.
Similar companies
Follow NVAX
Get an email when Novavax Inc files with the SEC: results, executive changes, material agreements and annual reports.
Follow NVAX: get an email when it filesWhere the numbers come from
Financial figures are the values Novavax Inc tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.